Product Profiles: COPD in China – Novel therapies to diversify treatment options

Published by: Datamonitor

Published: Nov. 14, 2011 - 89 Pages


Table of Contents

Executive Summary
Strategic scoping and focus
Datamonitor key findings
Related reports
OVERVIEW
Catalyst
Summary
MARKET DEFINITION AND OVERVIEW
Market definition
Product overview
MARKETED PRODUCT PROFILES
Seretide (fluticasone/salmeterol; GlaxoSmithKline)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Ventolin (salbutamol; GlaxoSmithKline)
Drug profile
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Spiriva (tiotropium bromide; Boehringer Ingelheim)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Combivent (salbutamol/ipratropium; Boehringer Ingelheim)
Drug profile
SWOT analysis
Product positioning
Clinical and commercial attractiveness
An Sai Ma (doxofylline; HLJ Fuhe Huaxing Pharmaceuticals)
Drug profile
SWOT analysis
Product positioning
Clinical and commercial attractiveness
PIPELINE PRODUCT PROFILES
Onbrez (indacaterol; Novartis)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet need
Clinical and commercial attractiveness
Daxas (roflumilast; Nycomed)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet need
Clinical and commercial attractiveness
Relovair (fluticasone furoate/vilanterol trifenatate; GlaxoSmithKline)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet need
Clinical and commercial attractiveness
QVA149 (indacaterol/glycopyrronium bromide; Novartis)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet need
Clinical and commercial attractiveness
Olodaterol/tiotropium (Boehringer Ingelheim)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet need
Clinical and commercial attractiveness
Other drugs in development for COPD
OPC-6535 (tetomilast; Otsuka)
BIBLIOGRAPHY
Journal papers
Websites
Datamonitor reports
APPENDIX
Contributing experts
Datamonitor drug assessment scorecard methodology
Conferences attended
Report methodology

Abstract

Introduction

Spiriva has a strong reputation with Chinese physicians due to its robust efficacy, making it the gold standard monotherapy in COPD treatment. Spiriva’s inclusion in the 2009 National Reimbursement Drug List has further driven uptake given the high importance of affordability in Chinese COPD treatment.

Features and benefits
  • Understand Chinese market dynamics and the role that reimbursement plays in determining success in the COPD market.
  • Learn from successful marketing strategies used for key COPD brands in China.
  • Assess how pipeline products compare to each other and how they will compete with established therapies.
  • Review important clinical developments for key pipeline agents in China with analysis of the latest clinical trial data.
  • Access Datamonitor’s independent clinical and commercial assessment of marketed brands and key pipeline agents for COPD in China.
Highlights

Although methylxanthine has been largely withdrawn from COPD treatment in major markets, it is still extensively used in China at various disease stages. The drug remains a popular choice for patients with lower income, and the greater tolerance of the drug in Chinese patients has further limited the decline in its prescription.A number of novel products are moving through the COPD pipeline. Novartis’s once-daily LABA Onbrez will pose a threat to twice-daily LABAs and is expected to be positioned as an add-on therapy to Spiriva. Onbrez is also the LABA component of QVA149, a LABA/LAMA combination forecast to reach the Chinese market at the end of 2014.

Your key questions answered
  • How do currently marketed treatments of COPD in China compare to one another?
  • What restrictions will pipeline products for COPD face if approved for the Chinese market?
  • Which pipeline products will need to compete with currently established treatments, and which will be positioned as add-on therapies?
  • How have companies utilized pricing strategies to see success in the COPD market in China?


Get full details about this report >>
 
Learn more about this product


Price and delivery options
Search Inside Report

US: 800.298.5699

Int'l: +1.240.747.3093

 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.